Listen on the go
CORRECT!
Next question
touchCARDIO touchCARDIO
Atherosclerosis
Watch Time: 7 mins

Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol

Copy Link
Published Online: May 3rd 2022

The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial.

Questions:

  1. What is vupanorsen and what is the rationale for its use as a lipid-lowering agent? (00:19)
  2. What are the aims, design, and eligibility criteria of the TRANSLATE-TIMI 7 clinical trial? (01:34)
  3. What were the efficacy and safety findings of the study? (03:02)
  4. What will be the next step in the clinical development of vupanorsen in this indication? (04:25)
  5. What are the other potential indications of vupanorsen? (06:15)

Disclosures: Brian Bergmark discloses grant/research support from Pfizer, AstraZeneca and Ionis.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the American College of Cardiology Annual Meeting 2022

Share this Video
Related Videos In Atherosclerosis
Atherosclerosis
Developed by Touch
Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
Watch Time: 7 mins

The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial. Questions: What is vupanorsen and what is […]

Atherosclerosis
Developed by Touch
Paul Ridker, ACC 2022: Secondary analysis of the CANTOS trial of the inflammatory hypothesis of atherothrombosis and chronic kidney disease
Watch Time: 6 mins

The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘Secondary Analysis of the CANTOS Trial: […]

Atherosclerosis
Charalambos Antoniades, ESC 2021 – The Fat Attenuation Index
Watch Time: 8 mins 45

Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the fat attenuation index and its use in clinical decision making from the virtual ESC Congress 2021. Questions Can you tell us a little about the fat attenuation index (FAI) and how it can be […]

Trending In Atherosclerosis:

Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
Atherosclerosis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72